Oral Antidiabetic Agents

@article{Krentz2012OralAA,
  title={Oral Antidiabetic Agents},
  author={Andrew J. Krentz and Clifford J. Bailey},
  journal={Drugs},
  year={2012},
  volume={65},
  pages={385-411}
}
Type 2 diabetes mellitus is a progressive and complex disorder that is difficult to treat effectively in the long term. The majority of patients are overweight or obese at diagnosis and will be unable to achieve or sustain near normoglycaemia without oral antidiabetic agents; a sizeable proportion of patients will eventually require insulin therapy to maintain long-term glycaemic control, either as monotherapy or in conjunction with oral antidiabetic therapy. The frequent need for escalating… Expand
View on Springer
ncbi.nlm.nih.gov
477 Citations
Highly Influential Citations
3
Background Citations
49
Methods Citations
1
Results Citations
2

477 Citations

Citation Type

Citation Type

Drug Resistance in Diabetes
TLDR
This chapter gives the knowledge about diabetes mechanism of drug resistance, classification, pathophysiology and its management and further research is needed to be done in order to prevent the world from this widespread disease. Expand
New oral antidiabetic agents
TLDR
This work focuses on the new agents used in the latest years and the overcoming ones in future, in particular incretin-based therapies, drugs inhibiting kidney glucose reabsorption (SGLT2 inhibitors), and glucokinase activators. Expand
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
TLDR
The pharmacokinetics, pharmacodynamics and safety profiles, including cardiovascular safety, of currently available therapies for management of hyperglycaemia in patients with T2DM are assessed within the context of disease pathogenesis and natural history. Expand
Current strategies for evaluating, monitoring, and treating type 2 diabetes mellitus.
  • J. Unger
  • Medicine
  • The American journal of medicine
  • 2008
TLDR
Physicians should strive to help patients understand and reach the targets for control that the authors know to be beneficial for the majority of individuals, and intensify therapy early during the course of the disease process, using the most effective and acceptable therapies available, and maintaining the lowest and safest HbA1c levels for as long as possible. Expand
Current state of type 2 diabetes management.
  • M. Molitch
  • Medicine
  • The American journal of managed care
  • 2013
TLDR
A class of medications that inhibit the sodium glucose cotransporter 2 in the kidney show promise in their ability to decrease glucose reabsorption and increase glucose excretion, and have recently been approved by the US Food and Drug Administration. Expand
Current Management Strategies for Coexisting Diabetes Mellitus and Obesity
TLDR
Whenever insulin is required by the obese diabetic patient after failure to respond to oral drugs, it should be preferably prescribed in combination with an oral agent, more particularly metformin or acarbose, or possibly a thiazolidinedione. Expand
The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus
TLDR
The metabolic relationships between oral antihyperglycemic drugs from the aspect of gut, microbiota, hormones, β cell function, central nervous system, and other cellular mechanisms are discussed. Expand
Pleiotropic effects of anti-diabetic drugs: A comprehensive review.
TLDR
This review is an updated, comprehensive review, describing the protective role of various classes of anti-diabetic drugs in mitigating the macro and micro vascular complications of diabetes mellitus, and differentiating these drugs on the basis of their mode of action. Expand
Current anti-diabetic agents and their molecular targets: A review.
TLDR
This review offers a medium on which future drug design and development toward diabetes management may be modelled (i.e. optimization via structural derivatization), as many of the drug candidates highlighted show promise as an effective anti-diabetic chemotherapy. Expand
Discovery of Orally Active, Potent, and Selective Benzotriazole‐Based PTP1B Inhibitors
TLDR
Obesity-induced type 2 diabetes mellitus is clinically characterized by increased blood glucose levels, either due to defects in insulin secretion, insulin resistance, or both, and there is an urgent need to develop novel agents for glycemic control that can complement existing therapies and prevent the progression of secondary complications associated with diabesity. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 142 REFERENCES
Is There a Role for α-Glucosidase Inhibitors in the Prevention of Type 2 Diabetes Mellitus?
TLDR
If the ongoing EDIT trial confirms the positive results of the recent STOP-NIDDM trial, acarbose could be used, either as an alternative or in addition to changes in lifestyle, to delay development of diabetes in patients with IGT. Expand
Antidiabetic Drugs Present and Future
TLDR
There is evidence that, like metformin, thiazolidinediones also improve cardiovascular risk factors such as dyslipidaemia and fibrinolysis, and whether these differences will translate into clinical benefit remains to be seen. Expand
Type 2 diabetes mellitus: what is the optimal treatment regimen?
  • D. Bell
  • Medicine
  • The American journal of medicine
  • 2004
TLDR
The benefits of treatment with sensitizers vis à vis alpha-glucosidase inhibitors and secretagogues as part of a comprehensive treatment algorithm for type 2 diabetes mellitus are outlined. Expand
Meglitinide Analogues in the Treatment of Type 2 Diabetes Mellitus
TLDR
The short action of these compounds and biliary elimination makes repaglinide and nateglinide especially suitable for patients with type 2 diabetes mellitus who would like to have a more flexible lifestyle, need more flexibility because of unplanned eating behaviour and support the empowerment and compliance of the patient. Expand
Comparative Tolerability Profiles of Oral Antidiabetic Agents
TLDR
The sulphonylureas and the biguanides are widely used as adjuncts to dietary measures in the treatment of non-insulin-dependent diabetes mellitus (NIDDM) and are generally well tolerated, although pharmacokinetic differences between these agents have important clinical implications. Expand
Insulinotropic meglitinide analogues
TLDR
The emergence of new classes of oral agent with a more specific mode of action provides, for the first time, an opportunity to restore early-phase insulin release in type 2 diabetes. Expand
A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus
TLDR
Given the 4 decades of clinical experience with metformin, its antihyperglycaemic efficacy and benefits against Syndrome X, met formin offers a very favourable risk-benefit assessment when compared with the chronic morbidity and premature mortality among patients with type 2 diabetes mellitus. Expand
Oral antihyperglycemic therapy for type 2 diabetes: scientific review.
TLDR
With few exceptions, the available oral antidiabetic agents are equally effective at lowering glucose concentrations and their mechanisms of action are different, however, and as a result they appear to have distinct metabolic effects. Expand
Metformin: An Update
TLDR
Treatment with an insulin-sensitizing agent, such as metformin, in patients with type 2 diabetes mellitus may correct several of the primary pathophysiological abnormalities of the metabolic syndrome. Expand
Thiazolidinediones: a new class of antidiabetic drugs
  • C. Day
  • Medicine
  • Diabetic medicine : a journal of the British Diabetic Association
  • 1999
TLDR
Thiazolidinediones have been shown to improve insulin sensitivity in a range of insulin‐resistant states including obesity, impaired glucose tolerance (IGT) and polycystic ovary syndrome (PCOS). Expand
...
1
2
3
4
5
...